Dana-farber-cancer Institute Inc.

Emory University

Medtronic, Inc.

Nkt Therapeutics Inc.

James Peter Gregson

Francis J Carr

Timothy David Jones

Gordon James Freeman

Rafi Ahmed

Lisa Lynn Shafer

Tim Jones

Dawn Ann Bembridge

Francis Joseph Carr

Alemseged Truneh

Timothy D Jones

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infections diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-1, and/or PD-L2 activity (e.g., persistent infectious diseases autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

Methods of treatment to suppress an immune response are provided. The method comprises administering to a subject in need of treatment a naked blocking antibody that binds selectively iNKT cells in an amount effective to suppress the subject's iNKT cell function. Compositions comprising, an isolated, humanized antibody that binds selectively iNKT cells are also provided.

Humanized antibodies to iNKT

Human anti-PD-1 antibodies and uses therefor

Humanized anti-A&#x3b2; antibodies derived from a murine antibody directed to a N-terminal epitope of A&#x3b2; are described. The humanized antibodies have reduced or no human T cell epitopes and bind A&#x3b2; with an affinity similar to that of the murine antibody.

Humanized anti-amyloid beta antibodies

Anti-PD-L1 antibodies and uses therefor

Growing community of inventors

Essex, United Kingdom

James Peter Gregson